{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.94","value":"58.7"},{"groupId":"OG001","spread":"1.96","value":"60.3"}]}],"title":"6 hours post-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.16","value":"50.8"},{"groupId":"OG001","spread":"2.18","value":"52.0"}]}],"title":"12 hours post-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.39","value":"39.1"},{"groupId":"OG001","spread":"2.41","value":"45.0"}]}],"title":"24 hours post-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.45","value":"29.5"},{"groupId":"OG001","spread":"2.48","value":"38.9"}]}],"title":"48 hours post-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.33","value":"22.1"},{"groupId":"OG001","spread":"2.35","value":"31.9"}]}],"title":"72 hours post-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.25","value":"19.2"},{"groupId":"OG001","spread":"2.27","value":"27.7"}]}],"title":"4 days post-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.23","value":"16.4"},{"groupId":"OG001","spread":"2.25","value":"25.4"}]}],"title":"5 days post-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.20","value":"14.3"},{"groupId":"OG001","spread":"2.22","value":"22.3"}]}],"title":"6 days post-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.18","value":"14.0"},{"groupId":"OG001","spread":"2.20","value":"19.5"}]}],"title":"7 days post-dose"}],"denoms":[{"counts":[{"groupId":"OG000","value":"112"},{"groupId":"OG001","value":"114"}],"units":"Participants"}],"description":"Patients scored their pain intensity in the joint most affected at Baseline on a 0-100 mm VAS, ranging from no pain (0) to unbearable pain (100), from 6 hours to 7 days post-dose. Scores on the 100 mm linear scale were measured to the nearest millimeter from the left. The ANCOVA analysis included treatment group, Baseline VAS score, and body mass index (BMI) at Baseline as covariates.","dispersionType":"Standard Error","groups":[{"description":"Participants received 1 subcutaneous (sc) injection of canakinumab 150 mg and 1 intramuscular (im) injection of placebo to triamcinolone acetonide on Day 1. Participants could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose.","id":"OG000","title":"Canakinumab 150 mg"},{"description":"Participants received 1 intramuscular injection of triamcinolone acetonide 40 mg and 1 sc injection of placebo to canakinumab on Day 1. Participants could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose.","id":"OG001","title":"Triamcinolone Acetonide 40 mg"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"Full Analysis Set (FAS) consisted of all patients as randomized in the core study who had taken at least one dose of study drug.","reportingStatus":"POSTED","timeFrame":"6, 12, 24, 48, and 72 hours; and 4, 5, 6, and 7 days post-dose (randomization)","title":"Self-assessed Pain Intensity in the Joint Most Affected at Baseline Measured on a Visual Analog Scale (0-100 mm VAS)","type":"SECONDARY","unitOfMeasure":"mm"}